AKTX Quote, Financials, Valuation and Earnings

Ascendis Pharma AS has a net margin of -- compared to Akari Therapeutics PLC's net margin of -171.53%. Akari Therapeutics PLC's return on equity of -- beat Ascendis Pharma AS's return on equity of --.

Akari Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 8147.42%. On the other hand Ascendis Pharma AS has an analysts' consensus of $189.82 which suggests that it could grow by 39.33%. Given that Akari Therapeutics PLC has higher upside potential than Ascendis Pharma AS, analysts believe Akari Therapeutics PLC is more attractive than Ascendis Pharma AS.

Akari Therapeutics PLC has a beta of 0.791, which suggesting that the stock is 20.903% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.675, suggesting its less volatile than the S&P 500 by 32.529%.

Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend.

Akari Therapeutics PLC quarterly revenues are --, which are smaller than Ascendis Pharma AS quarterly revenues of $63.6M. Akari Therapeutics PLC's net income of -$2.9M is higher than Ascendis Pharma AS's net income of -$109.1M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus 21.92x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals PLC has a net margin of -- compared to Akari Therapeutics PLC's net margin of --. Akari Therapeutics PLC's return on equity of -- beat Biodexa Pharmaceuticals PLC's return on equity of --.

Akari Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 8147.42%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of -- which suggests that it could grow by 105.52%. Given that Akari Therapeutics PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe Akari Therapeutics PLC is more attractive than Biodexa Pharmaceuticals PLC.

Akari Therapeutics PLC has a beta of 0.791, which suggesting that the stock is 20.903% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.447, suggesting its more volatile than the S&P 500 by 44.69%.

Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Akari Therapeutics PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. Akari Therapeutics PLC's net income of -$2.9M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus 3.52x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Cellectis SA has a net margin of -- compared to Akari Therapeutics PLC's net margin of -142.32%. Akari Therapeutics PLC's return on equity of -- beat Cellectis SA's return on equity of -79.78%.

Akari Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 8147.42%. On the other hand Cellectis SA has an analysts' consensus of -- which suggests that it could grow by 314.08%. Given that Akari Therapeutics PLC has higher upside potential than Cellectis SA, analysts believe Akari Therapeutics PLC is more attractive than Cellectis SA.

Akari Therapeutics PLC has a beta of 0.791, which suggesting that the stock is 20.903% less volatile than S&P 500. In comparison Cellectis SA has a beta of 3.093, suggesting its more volatile than the S&P 500 by 209.338%.

Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

Akari Therapeutics PLC quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $16.2M. Akari Therapeutics PLC's net income of -$2.9M is higher than Cellectis SA's net income of -$23.1M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus 4.96x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

DBV Technologies SA has a net margin of -- compared to Akari Therapeutics PLC's net margin of --. Akari Therapeutics PLC's return on equity of -- beat DBV Technologies SA's return on equity of --.

Akari Therapeutics PLC has a consensus price target of --, signalling upside risk potential of 8147.42%. On the other hand DBV Technologies SA has an analysts' consensus of -- which suggests that it could grow by 590.04%. Given that Akari Therapeutics PLC has higher upside potential than DBV Technologies SA, analysts believe Akari Therapeutics PLC is more attractive than DBV Technologies SA.

Akari Therapeutics PLC has a beta of 0.791, which suggesting that the stock is 20.903% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.642, suggesting its less volatile than the S&P 500 by 35.828%.

Akari Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Akari Therapeutics PLC pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

Akari Therapeutics PLC quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Akari Therapeutics PLC's net income of -$2.9M is higher than DBV Technologies SA's net income of -$30.4M. Notably, Akari Therapeutics PLC's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Akari Therapeutics PLC is -- versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.